Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of Genz-112638 versus Cerezyme in stable type 1 Gaucher disease
NL-OMON33436Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Sep 2009
- Modality
- Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Gaucher disease type 1 (GD1) comparing Genz-112638 with Cerezyme (2 arms). Primary endpoint: Percentage of patients remaining stable through 52 weeks. Planned start Sep 2009; status: not yet recruiting.
02
Drugs
eliglustatimiglucerase
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on NL-OMON33436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33436.